Hotchkis & Wiley Capital Management LLC Acquires 51,420 Shares of ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Hotchkis & Wiley Capital Management LLC significantly increased its holdings in ANI Pharmaceuticals by 89.9% during the first quarter, now owning 108,600 shares valued at approximately $7.27 million.
• ANI Pharmaceuticals reported a $1.80 EPS for the last quarter, exceeding estimates, with revenue up 53.2% year over year, reaching $211.37 million.
• Several research firms have upgraded ANI Pharmaceuticals' stock, with Zacks Research and Wall Street Zen rating it as a "strong-buy", suggesting strong growth expectations moving forward.

Hotchkis & Wiley Capital Management LLC raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 89.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 108,600 shares of the specialty pharmaceutical company's stock after purchasing an additional 51,420 shares during the period. Hotchkis & Wiley Capital Management LLC owned approximately 0.50% of ANI Pharmaceuticals worth $7,271,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in ANI Pharmaceuticals by 68.3% in the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock valued at $10,565,000 after purchasing an additional 64,021 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of ANI Pharmaceuticals by 53.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock valued at $599,000 after buying an additional 3,112 shares during the period. Invesco Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock valued at $13,361,000 after buying an additional 2,022 shares during the period. GAMMA Investing LLC boosted its holdings in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of ANI Pharmaceuticals by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock valued at $15,959,000 after buying an additional 2,220 shares during the period. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:ANIP traded up $0.97 during trading on Friday, hitting $93.50. 283,240 shares of the company were exchanged, compared to its average volume of 751,359. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -121.43 and a beta of 0.61. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $93.72. The firm has a fifty day moving average price of $73.39 and a two-hundred day moving average price of $67.07. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business's quarterly revenue was up 53.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.02 EPS. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the completion of the transaction, the senior vice president directly owned 173,226 shares in the company, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Nikhil Lalwani sold 56,960 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer owned 411,219 shares of the company's stock, valued at $35,336,048.67. This represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 405,538 shares of company stock worth $35,690,131. Corporate insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several research analyst reports. Piper Sandler reiterated an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. HC Wainwright restated a "buy" rating and set a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, August 11th. Zacks Research upgraded shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $84.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.